Abstract：
UNASSIGNED: Our study aims to provide an enhanced comprehension of systemic lupus erythematosus (SLE) burden in United Arab Emirates (UAE), over a five-year period from payer and societal perspective.
UNASSIGNED: A Markov model was established to simulate the economic consequences of SLE among UAE population. It included four health states: i) the three phenotypes of SLE, representing mild, moderate, and severe states, and ii) death. Clinical parameters were retrieved from previous literature and validated using the Delphi panel-the most common clinical practice within the Emirati healthcare system. We calculated the disease management, transient events, and indirect costs by macro costing. One-way sensitivity analysis was conducted.
UNASSIGNED: The estimated number of SLE patients in our study was 13,359. The number of SLE patients with mild, moderate, and severe phenotypes was 3,914, 8,109, and 1,336, respectively. Disease management costs, including treatment of each phenotype and disease follow-up, were AED 2 billion ($0.89 billion), whereas the costs of transient events (infections, flares, and consequences of SLE-related organ damage) were AED 1 billion ($0.44 billion). The productivity loss costs among adult-employed patients with SLE in the UAE were estimated at AED 7 billion ($3.1 billion). The total SLE cost over five years from payer and societal perspectives is estimated at AED 3 ($1.3 billion) and 10 billion ($4.4 billion), respectively. Additionally, the costs per patient per year from the payer and societal perspectives were AED 45,960 ($20,610) and AED 148,468 ($66,578), respectively.
UNASSIGNED: Our findings demonstrate that the burden of SLE in the UAE is enormous, mainly because of the costly complications and productivity loss. More awareness should be created to limit the progression of SLE and reduce the occurrence of flares, necessitating further economic evaluations of novel treatments that could help reduce the economic consequences of SLE in the UAE.
UNASSIGNED: A Markov model was established to simulate the economic consequences of SLE among UAE population. It included four health states: i) the three phenotypes of SLE, representing mild, moderate, and severe states, and ii) death. Clinical parameters were retrieved from previous literature and validated using the Delphi panel-the most common clinical practice within the Emirati healthcare system. We calculated the disease management, transient events, and indirect costs by macro costing. One-way sensitivity analysis was conducted.
UNASSIGNED: The estimated number of SLE patients in our study was 13,359. The number of SLE patients with mild, moderate, and severe phenotypes was 3,914, 8,109, and 1,336, respectively. Disease management costs, including treatment of each phenotype and disease follow-up, were AED 2 billion ($0.89 billion), whereas the costs of transient events (infections, flares, and consequences of SLE-related organ damage) were AED 1 billion ($0.44 billion). The productivity loss costs among adult-employed patients with SLE in the UAE were estimated at AED 7 billion ($3.1 billion). The total SLE cost over five years from payer and societal perspectives is estimated at AED 3 ($1.3 billion) and 10 billion ($4.4 billion), respectively. Additionally, the costs per patient per year from the payer and societal perspectives were AED 45,960 ($20,610) and AED 148,468 ($66,578), respectively.
UNASSIGNED: Our findings demonstrate that the burden of SLE in the UAE is enormous, mainly because of the costly complications and productivity loss. More awareness should be created to limit the progression of SLE and reduce the occurrence of flares, necessitating further economic evaluations of novel treatments that could help reduce the economic consequences of SLE in the UAE.
摘要：
■我们的研究旨在提高对阿拉伯联合酋长国（UAE）系统性红斑狼疮（SLE）负担的理解，从付款人和社会的角度来看，在五年的时间里。
■建立了马尔可夫模型，以模拟阿联酋人口中SLE的经济后果。它包括四种健康状况：i)SLE的三种表型，代表温和，中度,和严重的国家，ii）死亡。从以前的文献中检索临床参数，并使用Delphi小组进行验证，Delphi小组是阿联酋医疗保健系统中最常见的临床实践。我们计算了疾病管理，瞬态事件,和按宏观成本计算的间接成本。进行了单因素敏感性分析。
■我们研究中SLE患者的估计人数为13,359。轻度SLE患者的数量,中度,严重表型分别为3,914、8,109和1,336。疾病管理成本，包括每种表型的治疗和疾病随访，是20亿迪拉姆（8.9亿美元），而短暂事件的成本(感染，耀斑,与SLE相关的器官损害的后果）为10亿迪拉姆（4.4亿美元）。阿联酋成年SLE患者的生产力损失成本估计为70亿迪拉姆（31亿美元）。从付款人和社会角度来看，五年来的SLE总成本估计为3迪拉姆（13亿美元）和100亿迪拉姆（44亿美元），分别。此外,从付款人和社会角度来看，每名患者每年的费用分别为45,960迪拉姆(20,610美元)和148,468迪拉姆(66,578美元)，分别。
■我们的研究结果表明，在阿联酋，SLE的负担是巨大的，主要是因为昂贵的并发症和生产力损失。应该建立更多的意识来限制SLE的进展并减少耀斑的发生，需要对新疗法进行进一步的经济评估，以帮助减少阿联酋SLE的经济后果。
■建立了马尔可夫模型，以模拟阿联酋人口中SLE的经济后果。它包括四种健康状况：i)SLE的三种表型，代表温和，中度,和严重的国家，ii）死亡。从以前的文献中检索临床参数，并使用Delphi小组进行验证，Delphi小组是阿联酋医疗保健系统中最常见的临床实践。我们计算了疾病管理，瞬态事件,和按宏观成本计算的间接成本。进行了单因素敏感性分析。
■我们研究中SLE患者的估计人数为13,359。轻度SLE患者的数量,中度,严重表型分别为3,914、8,109和1,336。疾病管理成本，包括每种表型的治疗和疾病随访，是20亿迪拉姆（8.9亿美元），而短暂事件的成本(感染，耀斑,与SLE相关的器官损害的后果）为10亿迪拉姆（4.4亿美元）。阿联酋成年SLE患者的生产力损失成本估计为70亿迪拉姆（31亿美元）。从付款人和社会角度来看，五年来的SLE总成本估计为3迪拉姆（13亿美元）和100亿迪拉姆（44亿美元），分别。此外,从付款人和社会角度来看，每名患者每年的费用分别为45,960迪拉姆(20,610美元)和148,468迪拉姆(66,578美元)，分别。
■我们的研究结果表明，在阿联酋，SLE的负担是巨大的，主要是因为昂贵的并发症和生产力损失。应该建立更多的意识来限制SLE的进展并减少耀斑的发生，需要对新疗法进行进一步的经济评估，以帮助减少阿联酋SLE的经济后果。
